GlassScriptPhysician profile
Cesar E Ayala Rodriguez
NPI 1104156728
$8,012.67
in general payments reported to CMS, 2019-2025
34 companies · $2,814 in 2025
The $2,814 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $265 · 2021: $1,234 · 2022: $936 · 2023: $1,229 · 2024: $1,300 · 2025: $2,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,015 · Education: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,014.50 |
| Education | $328.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,411.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $820.13 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $576.04 | 2021-2025 | Versacross Access Solution, Farapulse |
| E.R. Squibb & Sons, L.L.C. | $523.36 | 2020-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $507.75 | 2021-2025 | Verquvo, Capvaxive |
| Alnylam Pharmaceuticals INC. | $466.69 | 2022-2025 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $412.14 | 2022-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $383.04 | 2023-2025 | |
| Amgen INC. | $374.29 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $366.62 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.69 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $210.28 | 2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $187.06 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $187.03 | 2019-2021 | |
| Bridgebio Pharma, INC. | $186.01 | 2025 | Attruby |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $150.27 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $130.43 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $111.15 | 2025 | Recorlev |
| Kestra Medical Technology Services, INC. | $110.33 | 2025 | Assure Wcd |
| Scpharmaceuticals INC. | $108.68 | 2025 | |
| Medtronic, INC. | $97.59 | 2021-2023 | Corevalve Evolut R |
| Abbott Laboratories | $78.63 | 2021-2023 | Cardiomems |
| Ge Healthcare | $65.42 | 2021 | |
| Cardiva Medical, INC. | $59.95 | 2019-2024 | Cardiva Vascade 6/7f Vcs |
| Abiomed | $40.97 | 2025 | |
| Lilly USA, LLC | $40.10 | 2025 | Mounjaro, Zepbound |
| Medicomp INC | $37.54 | 2025 | Telepatch Cardiac Monitor |
| Daiichi Sankyo INC. | $28.16 | 2022 | |
| Amryt Pharma Holdings LTD | $23.76 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $22.27 | 2023 | Arcalyst |
| Hologic Sales and Service, LLC | $20.34 | 2024 | Thinprep 2000 Processor, Aptima |
| Medtronic Vascular, INC. | $19.53 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $19.28 | 2024 | Arcalyst |
| Vifor Pharma, INC. | $13.73 | 2024 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Ayala Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.